Tandem Diabetes Care Community

NasdaqGM:TNDM Community

1 Narratives written by author
0 Comments on narratives written by author
5 Fair Values set on narratives written by author

Tandem Diabetes Care

AN

AnalystConsensusTarget

Consensus Narrative from 21 Analysts

FDA Approval Of Control-IQ+ Will Expand Market Reach In Type 2 Diabetes

Key Takeaways Operational improvements and new tech launches are expected to boost customer adoption and revenue, with increased market presence and margin expansion initiatives in Europe. FDA approval expands Tandem's addressable market for type 2 diabetes, while pharmacy channel access and product integration aim to drive sales growth.

US$40.80

FV

58.3% undervalued

8.74%

Revenue growth p.a.

0

0

3

6 days ago